1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MacKenzie Realty Capital reported fiscal 2026 results for the year ended June 30, 2026, with net revenues down 9% and net loss down 41%. The same day, its Board temporarily suspended the Preferred Share Repurchase Program so it can react to strategic alternatives that its financial advisor, Maxim Group LLC, may bring. The Board says the company's issuance of common stock in exchange for preferred shares added selling pressure on the common stock, and it expects to reassess the program in due course.
Net revenues were $20.01 million for fiscal 2026, down 9% from $22.06 million in fiscal 2025.
Net loss was $14.13 million, down 41% from $23.97 million; net operating loss was $15.61 million, down 33% from $23.46 million.
The Preferred Share Repurchase Program is temporarily suspended; the Board expects to reassess it in due course.
The company says there can be no assurance that it will enter into any strategic transaction.
KLX Energy Services completed its subscription rights offering on September 29, 2026, selling 24,975,001 shares at $1.49 each for $37.2 million in gross proceeds. Backstop holders of its 2030 Notes exchanged them for 59,273,445 shares, cutting outstanding principal by $94.0 million, and the company expects 105,677,168 shares outstanding afterward, so existing shareholders will be diluted. The 2030 Notes indenture was also amended to loosen leverage tests, which gives the company more covenant flexibility.
Rights offering: 24,975,001 shares sold at $1.49 per share for $37.2 million gross; $31.0 million for general corporate purposes and $6.2 million to redeem 2030 Notes at par on October 10, 2026
Backstop exchange: 59,273,445 shares issued to Backstop Parties; 2030 Notes principal reduced by $94.0 million; 105,677,168 shares expected outstanding
Indenture amended: total net leverage incurrence test relaxed from 2.50:1.00 to 3.00:1.00; maintenance covenant step-down reset to 4.50:1.00 starting with the quarter ending September 30, 2026
TTM Technologies completed its acquisition of Epiq Solutions on September 30, 2026, paying approximately $1.1 billion in cash, subject to customary adjustments. The purchase was funded with new term loans under a Third Amended and Restated Credit Agreement and proceeds from the company's 6.750% senior notes due 2034. The company expects the deal to be immediately accretive to adjusted EBITDA, moderately dilutive to non-GAAP diluted EPS in 2027, and accretive to non-GAAP diluted EPS in 2028.
Purchase price of approximately $1.1 billion in cash, paid to the seller on September 30, 2026, subject to working capital and other adjustments
New incremental facilities of $300 million term loan A and $800 million seven-year term loan B, with JPMorgan Chase Bank, N.A. as administrative agent
Company expects immediate accretion to adjusted EBITDA, moderate dilution to non-GAAP diluted EPS in 2027, and accretion in 2028
On September 29, 2026, Inogen agreed to sell substantially all assets of its U.S. oxygen rental business to Rotech Healthcare for an estimated up to $24.8 million, subject to post-closing reconciliation and payable in six installments. The filing also discloses a supply agreement with Rotech and a conditional increase in the share repurchase authorization to $45.0 million, effective only if the sale closes, which matters to shareholders because it removes a business with declining revenue while expanding capital return.
Purchase price is estimated at up to approximately $24.8 million, payable in six installments and subject to post-closing reconciliation.
The rental business generated $24.3 million of revenue in the first half of 2026, down 9.8% year over year.
Share repurchase authorization would rise from $30.0 million to $45.0 million and expire June 30, 2028 instead of December 31, 2027, but only upon closing.
The transaction is expected to close in the fourth quarter of 2026, and the rental business will be reported as discontinued operations starting with third-quarter 2026 results.
Progress Software reported fiscal third-quarter 2026 revenue of $246 million, down 2% year-over-year, while GAAP diluted earnings per share rose 25% to $0.55. The company raised its fiscal 2026 revenue and non-GAAP EPS guidance but cut its GAAP EPS guidance and expects a GAAP loss per share in the fourth quarter, and it closed its acquisition of Domo's AI and data platform business.
Q3 revenue was $246 million, down 2% year-over-year; ARR was $873 million, up 1% on a constant currency basis.
Fiscal 2026 revenue guidance was raised to $1,044 million-$1,052 million from $990 million-$1,002 million; GAAP diluted EPS guidance was cut to $1.18-$1.28 from $1.60-$1.74.
Fourth-quarter 2026 GAAP diluted loss per share is guided at $(0.41) to $(0.32); non-GAAP diluted EPS is guided at $1.24 to $1.33.
Q3 non-GAAP diluted EPS was $1.69, up 13% from $1.50; cash and cash equivalents were $113.7 million at quarter end.
Connect Biopharma reported preliminary topline results from its Phase 2 Seabreeze STAT COPD study of rademikibart as an add-on treatment for acute COPD exacerbations, with 159 participants randomized 1:1. The primary endpoint, treatment failure through Week 4, was reduced 81% versus placebo (p=0.0122), but the key secondary FEV1 result at Week 4 (70 mL improvement, p=0.1607) was not statistically significant. The company plans to engage the FDA on a Phase 3 program, and no timing was given.
Treatment failure through Week 4 was reduced 81% versus placebo (p=0.0122); 2 of 78 rademikibart participants and 11 of 81 placebo participants experienced treatment failure
FEV1 improved 70 mL at Week 4 versus placebo, but the result was not statistically significant (p=0.1607)
Any treatment-emergent adverse event occurred in 11 (14.1%) rademikibart participants versus 21 (25.9%) placebo participants
Connect plans to engage the FDA on a Phase 3 program; the filing gives no timing for that engagement
Talen's board named President Terry Nutt as chief executive effective January 1, 2027, succeeding Mac McFarland, who retires March 1, 2027. The same day, Talen entered $1.5 billion of accelerated share repurchase agreements, funded by selling about $1.5 billion of future PJM capacity revenues, and raised its remaining buyback authorization to $3.0 billion. For shareholders, the buyback reduces the share count, but the company says its adjusted free cash flow forecast for 2H 2026 through 2028 falls from about $4 billion to about $2.8 billion after the capacity sale.
Terry Nutt becomes CEO and joins the board on January 1, 2027; his base salary is set at $1,200,000, with a target bonus of 135% of base and a long-term incentive target of 700% of base.
Mac McFarland serves as Senior Advisor from January 1, 2027 until his retirement on March 1, 2027, and will receive $100,000 for those services.
The ASRs with Goldman Sachs & Co. LLC and Banco Santander cost $1.5 billion, with about 4.0 million shares initially received; the company expects them to be completed by the end of the first quarter of 2027 and says they would repurchase m
The capacity monetization covers PJM 2027/2028 and 2028/2029 delivery years, with Citi, at SOFR plus 200 basis points; the company targets net leverage of 3.5x by the second half of 2027.
Concentrix reported fiscal third-quarter 2026 revenue of $2,453.7 million, down 1.2% from a year earlier, and a GAAP net loss of $988.1 million, or $(16.24) per diluted share, driven by a non-cash $1,050.0 million goodwill impairment. Excluding non-GAAP items, diluted EPS rose 5.0% to $2.92, and the company raised its quarterly dividend to $0.37 per share. The company guided fourth-quarter non-GAAP diluted EPS to $2.86 to $2.98 and full-year 2026 non-GAAP diluted EPS to $10.97 to $11.09.
Revenue was $2,453.7 million, down 1.2% as reported and down 0.5% in constant currency
GAAP operating loss of $(910.3) million and net loss of $(988.1) million include a $1,050.0 million goodwill impairment
Non-GAAP operating income rose 1.3% to $309.0 million and non-GAAP net income rose 1.8% to $186.5 million
Quarterly dividend raised to $0.37 from $0.36, payable November 3, 2026; no shares repurchased in the quarter, with $396.6 million authorization remaining
Fox Factory Holding Corp. completed the sale of Wheelhouse Holdings, parent of baseball bat maker Marucci Sports, to Squared Up Holdings, an investor group led by Marucci senior management, on September 25, 2026. The Company received $200 million in cash, which it used to reduce borrowings under its credit facility, plus a $25 million subordinated note due December 31, 2026. The unaudited pro forma financial information filed with the 8-K shows a $120.1 million loss on the disposal, which weighs on shareholders even as it reduces debt.
Enterprise value of $225 million, paid as $200 million in cash and a $25 million subordinated convertible note
Note matures December 31, 2026; if unpaid, principal increases by $2.5 million and interest rises to 10% per year
Pro forma loss on disposal of $120.1 million and approximately $7.5 million in transaction costs
Pro forma six-month net sales fell to $647.6 million from $726.8 million historical
Workday reiterated its fiscal 2027 third-quarter and full-year guidance from August 27, 2026, except for GAAP operating margin, which it now expects to be roughly 20 to 21 percentage points below non-GAAP margin in the third quarter and about 19 points below for the full year. The company is reducing about 2.5% of its workforce, mainly in Product and Technology, and reducing leased office space, with charges of $65 million to $80 million that shareholders will see in GAAP results.
Reorganizations announced September 29, 2026 include a reduction of about 2.5% of current workforce, mainly in Product and Technology.
Charges of $65 million to $80 million: about $55 million to $70 million in fiscal Q3 and $10 million in fiscal Q4 2027.
Charges include $40 million to $55 million in cash severance and benefit costs, about $10 million in stock-based compensation, and about $15 million in office space impairment.
Employee actions are expected to be substantially complete by Q1 fiscal 2028; office actions by Q4 fiscal 2027.
uniQure presented additional data from its ongoing Phase I/II studies of AMT-130 for Huntington's disease, comparing treated patients with updated external controls. The 36-month analysis of all 15 high-dose patients showed 80% slowing on cUHDRS (nominal p=0.005) and 67% on TFC (nominal p=0.011), and the company says the BLA submission was based on 36-month data. The 48-month primary cUHDRS result showed 44% slowing but did not reach statistical significance (p=0.144), and the company notes that missing data and survivor bias in the updated control may understate the treatment effect.
36-month analysis of 15 high-dose patients: 80% slowing of cUHDRS decline (nominal p=0.005) and 67% slowing of TFC decline (nominal p=0.011)
48-month analysis of 12 high-dose patients: 44% slowing on cUHDRS (p=0.144, not significant) and 61% slowing on TFC (nominal p=0.008)
Data missingness in the updated Enroll-HD B control reached 53% at Month 48; data cutoff was June 30, 2026
Company says the BLA was submitted on 36-month data, which the FDA said at a June 2026 Type B meeting would be acceptable under the accelerated approval pathway
Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate (OLC) on September 29, 2026, with chemistry and manufacturing data from a new third-party drug product vendor. The company expects FDA acceptance within 30 days and a new PDUFA date six months from resubmission, following a June 2026 Complete Response Letter. The company also appointed Meredith S. Manning as an independent director effective October 1, 2026.
NDA resubmitted September 29, 2026, including CMC data from a new third-party drug product manufacturing vendor and 12 months of OLC drug product stability data.
Company anticipates FDA acceptance within 30 days; new PDUFA date expected six months from resubmission.
June 2026 CRL cited the same third-party manufacturing deficiencies as the June 2025 CRL; the original vendor's FDA inspection had not occurred as of September 29, 2026.
Meredith S. Manning appointed independent director effective October 1, 2026; cash, equivalents and marketable securities were $61.4 million as of June 30, 2026.
BeyondSpring agreed to sell its Chinese holding subsidiary, BeyondSpring Ltd., to Biolin Investment Limited. In exchange, Biolin's non-cash consideration is to fund the China portion of the Phase 3 DUBLIN-4 trial, and no cash is payable at closing. The company also set up an at-the-market program to sell up to 9,200,000 ordinary shares, which could dilute existing shareholders, and announced FDA Fast Track designation for Plinabulin.
Sale of BeyondSpring Ltd. to Biolin under a Share Purchase and Collaboration Agreement dated September 28, 2026; no cash paid to the company at closing
If Bulin misses the Target Enrollment within three years after closing, the investor must return part or all of the equity interests, with 100% returned if the shortfall is 90% or greater
ATM program with Citizens JMP Securities for up to 9,200,000 ordinary shares, with commission of up to 3.0% of gross proceeds
FDA granted Fast Track designation to Plinabulin and docetaxel for post-ICI non-squamous NSCLC; DUBLIN-4 plans approximately 442 patients with an interim analysis at 221 PFS events
Aldeyra Therapeutics said it intends to submit a Formal Dispute Resolution Request to the FDA, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026. The appeal's outcome and timing remain uncertain, and the filing states that the FDRR submission and meeting with the Office of New Drugs are expected in the fourth quarter of 2026.
Intends to submit an FDRR to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter for reproxalap
FDRR submission and a meeting with the Office of New Drugs are expected in the fourth quarter of 2026
Cash and cash equivalents were $45.1 million as of June 30, 2026; operational cash runway extended into 2029
Stewards completed its acquisition of Envy Pompano Beach, a 214-unit apartment and mixed-use property in Florida, on September 23, 2026, with a contractual price of $90.0 million paid partly in 14,263,025 newly issued common shares. The company must make $3.0 million monthly cash payments to sellers from October 2026 through April 2027, while 7,000,000 escrowed shares are cancelled over that period, and it took on a $47.7 million mortgage loan, which adds share dilution and cash obligations for shareholders.
Closed September 23, 2026; contractual price of $90.0 million, including 14,263,025 shares at a $3.00 contractual value per share and $44,557,435.93 of refinanced property debt
7,000,000 shares placed in escrow; $3.0 million cash payments due monthly from October 5, 2026 through April 5, 2027, with 1,000,000 escrowed shares cancelled per payment
$47.7 million LoanCore mortgage loan at one-month Term SOFR (3.35% floor) plus 3.60%, interest-only, maturing October 9, 2028
If shares are delisted from Nasdaq and not relisted within 120 days, the company must pay sellers $5.5 million per payment, subject to a $33.0 million aggregate cap
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
On September 28, 2026, AAR agreed to acquire a 65% controlling interest in MRO Holdings, an aircraft maintenance provider, for an estimated cash price of $1,819,174,310 plus Series A preferred stock with an agreed value of $780,825,690, subject to adjustments and closing conditions including regulatory approvals. The deal is expected to close in AAR's fiscal third quarter ending February 2027 and is to be funded partly by about $2.1 billion of new debt, which AAR expects to take net leverage to about 3.6x at closing. The filing also notes that a private investment in public equity offering may dilute existing stockholders, and the company's fiscal 2026 adjusted EBITDA was $401.1 million, up from $324.2 million.
Estimated cash purchase price of $1,819,174,310 and Series A preferred stock with an agreed value of $780,825,690, plus a $22,500,000 escrow deposit
Implied enterprise value of $4.0 billion; AAR expects about $2.1 billion of new debt financing and net leverage of about 3.6x at closing
Expected close in fiscal third quarter ending February 2027, subject to regulatory approvals; termination fee of $100,000,000 ($150,000,000 if the outside date is extended) applies if competition approvals fail
Press release shows fiscal 2026 net income of $187.7 million versus $12.5 million in fiscal 2025, and adjusted EBITDA of $401.1 million versus $324.2 million
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
MongoDB said CEO Chirantan Desai is stepping down, effective September 28, 2026, and that the board appointed former CEO Dev Ittycheria as interim President and CEO. The company said it has started a search for a permanent CEO and reaffirmed its fiscal 2027 and third-quarter guidance, which matters to shareholders because it changes the company's leadership while its outlook stays unchanged.
Chirantan Desai's resignation as President and CEO is effective September 28, 2026; the filing says it is not due to any disagreement with the company.
Dev Ittycheria, CEO from 2014 to 2025 and a board member since 2014, was appointed interim President and CEO effective September 28, 2026.
The board has begun a search for a permanent CEO and retained an executive search firm.
MongoDB reaffirmed its guidance for Q3 and full-year fiscal 2027 provided on September 1, 2026; an Investor Day is set for September 29, 2026, from 11:00 a.m. to 3:15 p.m. ET.
After the market close on September 25, 2026, a jury awarded $5.7 billion in damages to the plaintiff in Taction Technology, Inc. v. Apple Inc., a case in which Burford has a financial entitlement. Burford says that if the verdict were paid as is, its entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds, but the amount is likely to change in post-trial and appellate proceedings. For shareholders, the verdict is not a final judgment or cash received, and Burford warns it could recover substantially less or incur a total loss.
Jury verdict of $5.7 billion in damages, announced in a release dated September 28, 2026, after the market close on Friday, September 25, 2026
If paid as is, Burford's entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds
Apple has filed a motion for judgment as a matter of law, and the Federal Circuit will scrutinize large verdicts on appeal
Burford states that it could recover substantially less than the verdict amount or, in certain circumstances, incur a total loss
On September 24, 2026, Celularity closed the initial phase of a financing agreement signed September 23 for up to $25.0 million of senior secured convertible notes, raising $11.01 million in gross proceeds with warrants for about 4,037,000 shares. The filing also shows a September 18 settlement with Helena in which 2,000,000 additional shares were issued, and the notes and warrants could add substantial share dilution for existing holders.
Initial closing on September 24, 2026: $11.01 million in notes, convertible at $1.50 per share into about 7,340,000 shares
Warrants for about 4,037,000 shares, exercisable at $1.50 per share for five years
Notes bear 10% interest, mature 24 months after issue, and are secured by substantially all company and subsidiary assets
Helena settlement dated September 18, 2026: 700,000 shares issued on conversion of $1.197 million at $1.71 per share, plus 2,000,000 additional shares
The Marygold Companies (TMC), which indirectly owns United States Commodity Funds LLC, the general partner of United States Gasoline Fund (UGA), agreed on September 25, 2026 to be acquired by private equity firm Madison Dearborn Partners in an all-cash transaction. The deal would take TMC private and delist its stock from the New York Stock Exchange, and the filing says the deal may not be completed.
Agreement announced September 25, 2026 with Madison Dearborn Partners, a Chicago-based private equity firm
Transaction is expected to close in the first half of 2027 or earlier, subject to conditions
Closing requires approval of TMC stockholders, regulatory approvals and certain change-of-control approvals
TMC common stock will no longer be listed on the New York Stock Exchange after closing; the filing says there is no guarantee the deal will close
BCB Bancorp, Inc. said its bank agreed between September 21 and September 24, 2026 to sell problem loan portfolios with an aggregate unpaid principal balance of about $205.3 million as of June 30, 2026, with six purchasers. The company estimates a pre-tax loss of $43.3 million from the sales, to be recorded in the third quarter of 2026, and says the sales reduce balance sheet risk.
Six definitive agreements with six different purchasers; aggregate unpaid principal balance of about $205.3 million as of June 30, 2026
Portfolios include $180.7 million of commercial and multifamily real estate loans, $14.8 million of C&I loans, and $9.8 million of construction loans
Estimated pre-tax loss of $43.3 million, to be recorded in the third quarter of 2026
Five of the six sale transactions have closed; the last is expected to close before the end of the third quarter of 2026
Fathom Holdings and Neighborhood Intelligence (NXH) said on September 24, 2026, that they agreed to explore an alternative transaction in place of the merger agreement signed June 16, 2026. Under the proposal, NXH would contribute digital assets, led by its stake in tZERO, in exchange for newly issued Fathom shares, and would keep a controlling interest in Fathom. For shareholders, the original share exchange would be replaced by a deal that could change Fathom's ownership and control, and the companies say there is no assurance it will be completed.
The Original Merger Agreement, dated June 16, 2026, would be terminated once definitive documents are signed.
NXH's digital assets would be ascribed no less than $130 million in value, driven mainly by its approximately 38.8% direct and indirect stake in tZERO, subject to Fathom's validation.
NXH expects to keep a controlling interest in Fathom, and the final share count will be set in definitive agreements.
The deal remains subject to definitive agreements, Fathom and NXH board and Fathom stockholder approvals, an independent fairness opinion, and regulatory approvals.
Akamai entered two project plans under its existing Anthropic master services agreement, under which Anthropic has committed to pay about $11.6 billion over initial seven-year terms, subject to termination rights and delivery requirements. Akamai also issued Anthropic a warrant for Series B preferred stock that would convert into up to about 7.7 million common shares, roughly 5% of shares outstanding, with about 2% expected to vest on the initial commitment. Akamai said the deal is not expected to affect its 2026 revenue guidance but will raise 2026 capital expenditures by about $1.7 billion, and the filing's total capital expenditure estimate for the commitment is about $5.5 billion.
Anthropic has committed to pay about $11.6 billion in aggregate under Project Plans 2 and 3, each with an initial seven-year term, dated September 18, 2026
Warrant for 387,051 shares of Series B Non-Voting Convertible Preferred Stock, each convertible into 20 common shares, for up to 7,741,020 common shares on an as-converted basis
Total capital expenditures tied to the $11.6 billion commitment are estimated at about $5.5 billion, with about $1.7 billion more in 2026 capital expenditures for supply chain components including memory
Akamai anticipates no impact to its 2026 revenue guidance
TTM Technologies completed a $500 million private offering of 6.750% senior notes due 2034 on September 24, 2026. Proceeds, along with $300 million and $800 million of incremental term loans, are intended to fund the pending acquisition of EDS Intermediate Holding, LLC and related costs, with some funds possibly used to reduce revolver borrowings for the Swiss Technology Group AG acquisition. The filing adds substantial new debt and restricts dividends and other payments to shareholders, and the notes become subject to mandatory redemption if the EDS acquisition does not close by the November 15, 2026 outside date, subject to extension.
$500 million of 6.750% senior notes due October 1, 2034, priced at par and issued September 24, 2026
Planned financing also includes a $300 million incremental term loan A and an $800 million incremental term loan B
Notes must be redeemed at 100% of principal plus interest if the EDS acquisition does not close by November 15, 2026 (extendable to May 15, 2027 in certain cases)
Indenture limits dividends, share repurchases and certain other payments to shareholders
Sun Communities closed the sale of its UK business, Park Holidays, to Panther Bidco Limited, an affiliate of Aermont Capital, on September 22, 2026. The company received net cash proceeds of approximately $1.03 billion and says it expects to use them primarily for share repurchases, debt repayment and general corporate purposes. The company previously recorded a $1.1 billion valuation allowance charge on the UK business in the second quarter of 2026, and it will update its full-year 2026 outlook on its third quarter earnings call.
Closed on September 22, 2026; buyer Panther Bidco Limited is an affiliate of Aermont Capital
Net cash proceeds of approximately $1.03 billion after closing and transaction costs
Valuation allowance charge of $1.1 billion recorded in the three months ended June 30, 2026
Year-to-date through September 21, 2026, the company repurchased about 3.5 million shares for about $425 million
ONE Nuclear Energy LLC and Hennessy Capital Investment Corp. VII closed their business combination on September 23, 2026, and the combined company was renamed ONE Nuclear Energy Inc. Its common stock is expected to begin trading on Nasdaq under the ticker ONEN on or about September 24, 2026. Holders of 13,809,029 SPAC shares redeemed them for about $146.5 million, leaving about $2.2 million in the trust account before expenses, which the company says is intended to provide capital access for its 5 GW Louisiana Portfolio.
Holders of 13,809,029 Class A ordinary shares redeemed them at about $10.61 per share, for about $146.5 million in total
About $2.2 million remained in the Hennessy VII trust account after redemptions and forward purchase prepayments, before paying expenses
Nasdaq trading under ONEN expected on or about September 24, 2026
Portfolio includes Project Amberjack (up to 1 GW SMR), Project Cayman (2.88 GW gas plant) and Project Barracuda (1.2 GW gas plant)
Teamshares closed the sale of 225,000 shares of a new non-voting, non-convertible Series A Preferred Stock on September 23, 2026, at $990 per share, for an aggregate $222.75 million. The buyers are affiliates of a holder of more than 10% of the common stock, and the company says the proceeds are primarily intended to fund acquisitions. The preferred ranks ahead of common stock on dividends and liquidation, carries a 16.0% cash dividend rate, and includes covenants that restrict debt and require at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid.
225,000 Series A shares sold at $990 per share, or $222.75 million in aggregate, closed September 23, 2026
Liquidation preference of $1,000 per share; cumulative dividends of 16.0% per year if paid in cash or 18.0% if paid in kind
Ranks senior to common stock; non-voting and not convertible into common stock
Company may sell up to $75 million more of the same series; must keep at least $150 million of unrestricted cash until the existing credit facility is refinanced or repaid
NeoVolta reported fiscal 2026 results for the year ended June 30, 2026, with revenue up 58% to $13.3 million but a GAAP net loss of $21.5 million, or $(0.55) per share, versus $5.0 million in fiscal 2025. Fourth-quarter revenue fell sharply to approximately $13.5 thousand, and the company attributed the decline to federal tax law changes affecting residential and installer-channel sales, which matters to shareholders because losses widened as sales in that channel dropped.
Fiscal 2026 revenue was $13.3 million, up from $8.4 million in fiscal 2025.
Fourth-quarter GAAP net loss was $11.7 million, compared with $1.6 million a year earlier, including a $3.9 million provision for credit losses and bad debt expenses.
Cash and cash equivalents were $22.2 million at June 30, 2026, plus $3.2 million of restricted cash, following a May 2026 public offering.
The company reported adjusted EBITDA of $(12.8) million for fiscal 2026, its first period disclosing this non-GAAP measure, and a senior secured term loan provides $20 million in initial funding.
Arcturus said ARCT-810 was generally safe and well tolerated in an interim Phase 2 study in OTC deficiency, with reduced or maintained ammonia and reduced glutamine. The company also introduced its LUNAR 2.0 delivery platform, plans to add ARCT-2601 to the Phase 2 study near year-end, and entered a definitive agreement to acquire AI discovery company myNEO. The filing gives no financial figures, so the effect on shareholders is not quantified.
ARCT-810 reduced and/or maintained first morning fasting ammonia within the normal range; participants at the 0.5 mg/kg dose achieved mean glutamine values within the normal range during treatment
Weight gain was observed in all participants
Arcturus plans to begin dosing ARCT-2601 near year-end 2026 in OTCD patients aged 12 and older under an amended Phase 2 protocol
Acquisition of myNEO is subject to customary closing conditions and is expected to close in October 2026
Stitch Fix reported fourth quarter and full fiscal 2026 results, with revenue up 4.2% in the quarter and 6.4% for the year, and a narrower net loss than a year earlier. The company expects fiscal 2027 revenue of $1.310 billion to $1.360 billion, a decline of 2.8% to growth of 0.9%, citing a more challenging consumer environment and a lower active client base, which weighs on shareholder expectations for growth.
Q4 fiscal 2026 net revenue was $324.4 million, up 4.2% year-over-year, with a net loss of $2.1 million versus $8.6 million a year earlier.
Full fiscal 2026 net revenue was $1.35 billion, up 6.4%, with a net loss of $12.6 million versus $28.7 million; gross margin was 43.7%, down 70 basis points.
Fiscal 2027 net revenue outlook is $1.310 billion to $1.360 billion, or (2.8)% to 0.9% year-over-year; Q1 fiscal 2027 outlook is $323 million to $328 million, or (5.6)% to (4.1)%.
Active clients were 2.277 million at August 1, 2026, down 1.4% year-over-year; the company cited shipment timing and an August post-checkout offer flow change that reduced Fix volume in Q1.
On September 18, 2026, RAIN entered a binding letter of intent with Tensor Networks, a privately held developer of predictive AI infrastructure security technology, for an all-stock business combination. Tensor Networks' equity holders are expected to own about 90% of the combined company, leaving RAIN's existing shareholders with about 10%, before dilution from a planned PIPE financing. The deal still requires a definitive agreement, shareholder approval, and Nasdaq approvals, and there is no assurance it will be completed.
Tensor Networks' equity holders expected to own about 90% of fully diluted equity; RAIN shareholders about 10%, before PIPE dilution
Closing requires at least $25 million in gross proceeds from the PIPE financing and other sources
RAIN's Class B stock to be converted into Class A, and its debt to be converted, restructured, or forgiven; closing expected in the first quarter of 2027
Eric Frazier to become RAIN CEO and Randy Seidl to become President; either party may terminate if no definitive agreement is signed by November 20, 2026
CytoSorbents said it regained compliance with Nasdaq's $1.00 minimum bid price requirement after its closing bid price was at or above $1.00 for 10 consecutive trading sessions ending September 21, 2026, and Nasdaq closed that matter on September 22, 2026. The company still has not met Nasdaq's $35 million minimum market value of listed securities requirement, which it must meet by December 28, 2026, or it will receive a delisting notice, and the company states there is no assurance it will maintain its Nasdaq listing.
Nasdaq notified the company on September 22, 2026 that it regained compliance with the $1.00 minimum bid price requirement and closed the matter.
The company must have listed securities worth at least $35 million for 10 consecutive business days by December 28, 2026 to regain compliance with the market value requirement.
The company is evaluating actions and may consider increasing stockholders' equity to at least $2.5 million.
If the company does not regain compliance by December 28, 2026, it will receive a delisting notice and may appeal.
MillerKnoll reported first-quarter fiscal 2027 net sales of $923.4 million, down 3.4% from a year earlier, while diluted earnings per share rose to $0.38 from $0.29. The company said the quarter included about $10 million in net operating income from U.S. tariff refunds, worth $0.11 per diluted share, and it cut its full-year net sales outlook to $3.88 billion to $4.03 billion from $3.93 billion to $4.13 billion, while keeping its adjusted EPS outlook of $1.85 to $2.15 unchanged.
Net sales were $923.4 million, down 3.4% as reported and down 3.3% organically; orders were $913.9 million, up 3.2%.
Diluted EPS was $0.38 versus $0.29; adjusted diluted EPS was $0.53 versus $0.45, both including the $0.11 tariff refund benefit.
Full-year fiscal 2027 net sales outlook was lowered to $3.88 billion to $4.03 billion from $3.93 billion to $4.13 billion; adjusted EPS outlook stayed at $1.85 to $2.15.
Interim CEO Jeff Stutz was named in the release; the board declared a $0.1875 quarterly dividend payable October 15, 2026.
THOR Industries reported fiscal 2026 fourth-quarter and full-year results for the year ended July 31, 2026. Full-year net sales rose 0.3% to $9.61 billion, but net income attributable to THOR fell 31.3% to $177.5 million, and fourth-quarter net income fell 67.5% to $40.8 million. The company said it will not give fiscal 2027 guidance until later this fall, after industry events in September.
Fourth quarter: net sales of $2.31 billion, down 8.4%; diluted EPS of $0.78 versus $2.36 a year earlier
Fiscal 2026: net sales of $9.61 billion, up 0.3%; diluted EPS of $3.38 versus $4.84 a year earlier
Fiscal 2027 guidance withheld until later this fall; management expects a relatively flat retail environment and cost initiatives to improve earnings by more than $100 million annually once fully implemented
Repurchased $115.1 million of shares in fiscal 2026, including $34.3 million in the fourth quarter; reduced debt by $59.7 million
On September 15, 2026, Algorhythm Holdings closed its purchase of substantially all assets of Azure Energy, LLC, paying entirely in company securities valued at $23,000,000. The same day, CEO Gary Atkinson and CFO Alex Andre were terminated, Andrew Thompson became CEO, and the company issued a $4,025,000 secured note in an exchange for its Series A Preferred Stock. The common shares issued equal 19.99% of outstanding common stock, and the filing states the company is now seeking to shift its operating focus to renewable power.
Closed September 15, 2026; price of $23,000,000 paid in 4,076,312 common shares (19.99% of outstanding as of September 14, 2026) and 22,038 Series B Preferred shares
Option to buy 79.0286% of Azure S.R.L. equity for $30,000,000 within 36 months; up to 50% of exercise price payable in cash
Andrew Thompson appointed CEO effective September 15, 2026; Gary Atkinson and Alex Andre employment terminated not for cause; Atkinson also resigned from the board
Streeterville exchanged 3,500 Series A Preferred shares for a $4,025,000 Secured Pre-Paid Purchase #5 bearing 9% interest, maturing three years from September 15, 2026
Woodward plans to cease operations at its Santa Clarita, California, facility no later than December 2027 and move military flight control actuation production to its Spartanburg, South Carolina campus. The company also agreed to sell certain legacy product lines and the Santa Clarita campus, with that sale expected to close in fiscal 2027. Woodward expects cumulative pre-tax charges of $34 million to $47.5 million, mostly cash costs, which shareholders will bear as the actions are completed.
Estimated cumulative pre-tax charges of $34 million to $47.5 million, including $23 million to $29 million of employee-related costs
About 400 roles at the Santa Clarita facility are expected to be affected
Santa Clarita operations to cease no later than December 2027; Spartanburg facility expected to go online in summer 2027
Divestiture of certain product lines and the Santa Clarita campus expected to close in fiscal year 2027
IB Acquisition Corp. entered into an equity purchase facility of up to $50 million and a securities purchase agreement for senior secured convertible notes, both tied to its pending business combination with GNQ Insilico. The initial PIPE closing of $16,470,588 is set to occur just before the business combination closes, with potential additional closings up to $90 million. The notes carry a 12% interest rate and a 12-month maturity, and their conversion could dilute existing shareholders.
Equity purchase facility allows the company to sell up to $50.0 million of Class A common stock to an institutional investor over up to 36 months.
Initial PIPE closing of $16,470,588 in senior secured convertible notes, with potential additional closings up to $90,000,000.
PIPE notes bear 12% annual interest, rise to an 18% default rate, mature in 12 months and convert at an initial $10.00 per share.
Company issued a $675,000 convertible commitment note to the equity facility investor.
Optimum Communications said its previously issued financial statements for fiscal 2025 and the first half of 2026 should no longer be relied upon, because it failed to recognize non-cash deferred tax benefits tied to two earlier impairment charges on its cable franchise rights. The restatements are expected to reduce previously reported net losses, but the company also expects to report a material weakness in internal control over financial reporting related to income taxes.
The restatement covers the 10-K for fiscal 2025, the 10-Qs for the periods ended September 30, 2025, March 31, 2026 and June 30, 2026, and the financial statements of subsidiary CSC Holdings, LLC.
Reported net losses would decline by approximately $430 million for the three and nine months ended September 30, 2025 and the year ended December 31, 2025, and by approximately $720 million for the quarter ended March 31, 2026 and the six
Cash balances, revenues, capital expenditures, cash flows, EBITDA and loss before income taxes are not affected, according to the filing.
The Audit Committee concluded on September 16, 2026 that the affected statements should not be relied upon; the figures remain preliminary and may change.
National CineMedia, through subsidiary NCM Holdings, completed its acquisition of Captivate on September 18, 2026, for $275.0 million in cash, subject to adjustments. The deal was funded with a new $275.0 million term loan, a $25.0 million revolving facility with $10.0 million drawn, and cash on hand, and it repaid the company's existing U.S. Bank credit facility. The filing adds a larger debt load at a 7.00% SOFR margin, which shareholders should weigh against the expanded screen network.
Captivate acquisition closed September 18, 2026, for $275.0 million, including a $5.0 million escrow for post-closing adjustments
$275.0 million term loan fully funded; $25.0 million revolver with $10.0 million drawn at closing
Facilities mature September 18, 2031, with a 7.00% per annum margin for SOFR borrowings
Maximum Total Net Leverage Ratio of 5.00:1.00, stepping down to 4.50:1.00 by December 31, 2029
Mistras Group, Inc. (NYSE: MG) agreed on September 17, 2026 to be acquired by affiliates of H.I.G. Capital for $20.35 per share in cash, an enterprise value of approximately $866 million including debt. The price represents a premium of approximately 8% and 13% to the company's 30- and 90-day volume-weighted average share prices, and the stock would stop trading on the NYSE after the deal closes, which is expected in late 2026 or early 2027. Completion requires stockholder approval and regulatory clearances, and a 40-day go-shop period runs until October 27, 2026.
Merger consideration of $20.35 per share in cash, with stock options, RSUs and PRSUs also converted to cash payments
Premium of approximately 8% and 13% to the 30- and 90-day VWAP for the period ended September 17, 2026
Company termination fee of approximately $27.5 million; Parent termination fee of approximately $49.9 million
Go-shop period ends 11:59 p.m. Eastern Time on October 27, 2026; voting and support agreements cover approximately 31% of common stock
Paradium.AI announced a 10-year strategic platform agreement with Roundtable (RTB) under which Roundtable would take over certain operating functions and costs and receive a percentage of revenue from Paradium.AI's media brands. Separately, Roundtable agreed to buy shares from Paradium.AI's largest shareholder, Simplify Inventions, LLC, at $3.80 per share, but Paradium.AI receives no proceeds from that sale. The agreements are not yet effective and remain subject to conditions, including Roundtable's funding requirements, with closing scheduled for Q4 2026.
Roundtable agreed to buy Paradium.AI common stock from Simplify Inventions at $3.80 per share, which would give Roundtable about 49.5% of outstanding common stock.
Simplify would retain about 23.1% of Paradium.AI's outstanding common stock after the equity transaction.
Under the Platform Agreement, Roundtable would assume certain operating costs and receive a percentage of revenue from Paradium.AI's media brands, and receive a worldwide, perpetual license to certain technology assets.
In exchange for the license, Paradium.AI would receive Roundtable common stock, subject to closing price conditions; closing is scheduled for Q4 2026 but is not assured.
Upexi reported results for the fiscal year ended June 30, 2026, in a press release furnished as Exhibit 99.1. Total revenue rose to about $25.0 million from $15.8 million, but the net loss grew to $246.1 million, or $3.87 per share, from $13.7 million, or $1.73 per share, mainly due to $195.1 million of unrealized losses on digital assets, so shareholders face a much larger reported loss despite higher revenue.
Total revenue was about $25.0 million for fiscal 2026, compared with $15.8 million for fiscal 2025; digital asset revenue totaled $17.4 million.
Net loss was $246.1 million, or $3.87 per share, versus $13.7 million, or $1.73 per share, a year earlier, driven by $195.1 million of unrealized losses on digital assets.
General and administrative expenses rose to $26.4 million from $11.9 million, primarily reflecting the build-out of the treasury strategy.
Subsequent to year-end, the credit facility with BitGo Prime, LLC was amended to reduce the interest rate from 11.5% to 7.5% per year.
Lisata Therapeutics acquired Marea Therapeutics on September 17, 2026, issuing 1,793,129 shares of common stock and 211,365.213 shares of Series C convertible preferred stock to Marea stockholders. A concurrent private placement is expected to raise about $225 million in gross proceeds, and the filing says pre-transaction Lisata stockholders will hold about 2.39% of the company's common stock after the financing, which substantially dilutes existing holders.
Lisata issued 1,793,129 common shares and 211,365.213 Series C preferred shares to Marea stockholders; each preferred share converts into 1,000 common shares, subject to Lisata stockholder approval
Concurrent private placement with a gross value of about $225 million; the investors will receive Series C preferred shares at about $1,491.37 per share
Post-financing ownership: pre-transaction Lisata holders about 2.39%, former Marea holders about 59.54%, private placement investors about 38.07%
Lisata's CEO is Dr. David J. Mazzo; Dr. Josh Lehrer was newly appointed President and Chief Operating Officer of Lisata
Surgery Partners completed the sale of its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health on September 14, 2026, receiving aggregate consideration of about $796.6 million, with proceeds mainly used to pay down debt. Pro forma figures show lower revenue and a larger net loss attributable to the company for the periods presented, while management expects the deal to be accretive to adjusted earnings growth on an annual basis and to reduce balance sheet leverage. The company also updated its 2026 guidance to remove the sold hospitals' contribution for the rest of the year.
Sale closed September 14, 2026; gross proceeds of $797 million and $587 million in net cash proceeds at closing, subject to post-closing adjustments.
Balance sheet leverage, as defined in the credit agreement, is expected to improve by 30 basis points from 4.4x at the end of Q2 2026.
Updated 2026 guidance: revenue of $3.08 billion to $3.18 billion and Adjusted EBITDA of at least $489 million.
Pro forma net loss attributable to Surgery Partners was $69.2 million for the six months ended June 30, 2026, versus $50.9 million as reported; estimated gain on sale is $16.4 million.
On September 15, 2026, Hallador Energy and subsidiary Turtle Creek Gas Holdings closed a $600 million senior secured term loan with Kennedy Lewis Investment Management, with $550 million funded at closing. The company says the loan will fund turbine payments, development costs and construction of the 460-megawatt Turtle Creek gas project, which has an expected total cost of less than $800 million, but borrowings carry high interest rates and are secured by substantially all company and subsidiary assets.
$600 million senior secured term loan, with $550 million funded at closing and a $50 million delayed draw available for 12 months
Interest is 3.5% cash plus SOFR plus 4.50% payable in kind before commercial operation, then SOFR plus 8.00% in cash after operation begins
Loan matures three years after closing, with a two-year extension option requiring a 3.0% extension fee
Covenants include minimum unrestricted cash of $10 million starting with the test period ending December 31, 2026
Aethlon Medical and private biotech North Immunology signed a merger agreement in which North Immunology becomes a wholly owned subsidiary of Aethlon and the combined company is renamed North Immunology, Inc. Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company, while Aethlon stockholders also receive contingent value rights tied to proceeds, if any, from a sale or other monetization of its legacy Hemopurifier business.
Pre-merger Aethlon stockholders are expected to own about 4.75% of the combined company; North Immunology holders, including Private Placement investors, about 95.25%
Concurrent private placement expected to provide about $180 million, including about $34 million from converted notes; closing requires at least $175 million in proceeds
Expected to close in the first quarter of 2027; either party may terminate if not closed by June 17, 2027; termination fees are $300,000 (Aethlon) and $2,000,000 (North Immunology) in specified cases
Combined company expected to trade on Nasdaq Capital Market under ticker NRTX and be led by North Immunology's CEO
On September 11, 2026, ProFrac and the parties to its Alpine term loan signed Amendment No. 5, which cuts required quarterly principal payments to $0 through March 31, 2028 and extends maturity to February 15, 2030. The same day, $60 million of term loans was assigned to THRC Holdings and Farris C. Wilks, a co-founder and principal stockholder, and was repaid through the transfer of 2,306,806 Flotek shares owned by a ProFrac subsidiary, which gives the company near-term repayment relief but also a related-party transaction and tighter cash-flow and distribution terms.
Quarterly amortization reduced from $15 million to $0 for quarters ending September 30, 2026 through March 31, 2028, then $10 million per quarter.
Maturity extended from January 26, 2029 to February 15, 2030; PFP Holding may pay 675 basis points of interest in kind for 12 months from September 1, 2026.
$60 million of 2026 Term Loans assigned to THRC Holdings ($34.32 million) and Farris C. Wilks ($25.68 million) and cancelled in exchange for 2,306,806 Flotek shares.
Borrower must prepay 100% of excess cash flow each quarter, and company distributions are restricted to a $1 million annual basket.
ACP Holdings Acquisition Corp., a Cayman Islands special purpose acquisition company, signed a business combination agreement on September 15, 2026, under which May Mobility, Inc. would merge into a subsidiary of ACP and become a publicly listed company named May Mobility, Inc. on Nasdaq under the ticker MAY. ACP shareholders must approve the deal, and the 8-K sets an outside closing date of May 26, 2027, while the press release says closing is expected by year-end; the amount of gross proceeds depends on how many public shareholders redeem their shares.
Aggregate consideration to May Mobility holders is based on a $1.35 billion purchase price at $10.00 per share, with a pro forma enterprise value of approximately $1.4 billion.
Gross proceeds of up to $337 million, including up to $217 million from the ACP trust account (subject to redemptions) and a fully committed $120 million PIPE.
Closing is expected on or before May 26, 2027, subject to ACP and May Mobility shareholder approvals and other customary conditions.
May Mobility generated approximately $10 million in revenue and burned approximately $93 million in cash in 2025, according to the press release.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.